Similar effects of NLRP3 inhibition have also been reported in HFpEF models, in which MCC950 improves adverse cardiac and pulmonary artery remodeling, diastolic function, and overall exercise capacity, suggesting that the NLRP3-IL1β axis could be a potential therapeutic target for a broad range of HF[107]. The gene discussed is IL1B; the disease is hydrops fetalis.